Navigation Links
Dartmouth researchers find promising results with local hyperthermia of tumors

A combination of iron-oxide nanoparticles and an alternating magnetic field, which together generate heat, have activated an immune system response to tumors in mice according to an accepted manuscript by Dartmouth-Hitchcock Norris Cotton Center researchers in the journal Nanomedicine: Nanotechnology, Biology and Medicine released online on February 24, 2014.

"The study demonstrates that controlled heating of one tumor can stimulate an immune response that attacks another tumor that has not had the heat treatment," said Steve Fiering, PhD, Norris Cotton Cancer Center researcher and professor of Microbiology and Immunology, and of Genetics at the Geisel School of Medicine at Dartmouth. "This is one way to try to train the immune system to attack metastatic tumors that may not be recognized yet."

Researchers injected iron-oxide nanoparticles into the tumor and then activated those agents with magnetic energy. Researchers were able to activate antigen-presenting dendritic cells in the body's immune system. Dendritic cells somewhat serve as "quarterbacks" for body's immune system by calling for quick coordinated protection against an attack. The "quarterback" cells show the defensive "killer" T cells (CD8+ cells) who to attack and these cells then directly attack tumor cells and send out an alert system to engage other cells in the fight against the cancer. The combination of these two aspects of the immune response reduce risk of recurrence and discourage spreading or metastasis of the cancer. This result was observed in sites close to the primary tumor as well as distant sites. In the experiments conducted as part of this study the primary tumor resisted regrowth for one month following overheating.

The magnetic hyperthermia system used was developed by co-author P. Jack Hoopes, DVM, PhD co-director of Norris Cotton Cancer Center's Nanotechnology Working Group. "It enables very precise control of the heating to keep the temperature at a uniform 43 degrees C for as long as desired," said Fiering. "This precise control was the key to optimal immune stimulation."

The experiment included mouse colon and, melanoma cancers. Tumors responded to the heat by growing more slowly or disappearing completely. A higher temperature was better at eliminating primary tumors that were heat treated, but did not activate the immune system as well to find and attack metastatic tumors. Treatment of larger primary tumors generated a stronger immune response.

In the effort to develop better cancer treatments, the challenge is to find ways to cure metastatic disease. "The use of the immune system through cancer immunotherapy is a very exciting field currently and promises to contribute significantly to elimination of metastatic tumors," said Fiering. "The approach demonstrated is a good new option to be combined with other immunotherapy strategies for cancer therapy."

Standard cancer care involves surgery, but surgeons have few tools to guarantee the removal of every cancer cell, especially when there is unrecognized metastases in other anatomic locations. An approach like local hyperthermia one day might be used to kick start the immune system to ward off any cancer cells not removed by surgery to increase the chances of treatment success.


Contact: Donna Dubuc
The Geisel School of Medicine at Dartmouth

Related biology news :

1. Dartmouth-led research shows temperature, not snowfall, driving tropical glacier size
2. Dartmouth study shows US Southwest irrigation system facing decline after 4 centuries
3. Dartmouth researchers develop new tool to identify genetic risk factors
4. Dartmouth-led team gets $8 million grant to research arsenic in children
5. Dartmouth-led study shows diet alone can be significant source of arsenic
6. Dartmouth-led team discovers how plants avoid sunburn
7. Dartmouth researchers find there is no single sexy chin
8. Dartmouth researchers invent real time secondhand smoke sensor
9. Dartmouth neuroscientist finds free will has neural basis
10. Dartmouth research offers new control strategies for bipolar bark beetles
11. Mercury releases contaminate ocean fish: Dartmouth-led effort publishes major findings
Post Your Comments:
Related Image:
Dartmouth researchers find promising results with local hyperthermia of tumors
(Date:5/12/2016)... , a brand of Troubadour Research & ... Q1 wave of its quarterly wearables survey. A particular ... a program where they would receive discounts for sharing ... "We were surprised to see that so many ... CEO of Troubadour Research, "primarily because there are segments ...
(Date:5/3/2016)... May 3, 2016  Neurotechnology, a provider of ... MegaMatcher Automated Biometric Identification System (ABIS) , a ... projects. MegaMatcher ABIS can process multiple complex biometric ... combination of fingerprint, face or iris biometrics. It ... and MegaMatcher Accelerator , which have ...
(Date:4/28/2016)... 2016 First quarter 2016:   ... with the first quarter of 2015 The gross margin ... (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... unchanged, SEK 7,000-8,500 M. The operating margin for 2016 ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial ... Cary 5000 and the 6000i models are higher end machines that use the more ... the spectrophotometer’s light beam from the bottom of the cuvette holder. , FireflySci ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... YORK , June, 23, 2016  The Biodesign ... to envision new ways to harness living systems and ... Modern Art (MoMA) in New York City ... than 130 participating students, showcased projects at MoMA,s Celeste ... Paola Antonelli , MoMA,s senior curator of architecture ...
(Date:6/23/2016)... , June 23, 2016 Apellis Pharmaceuticals, ... 1 clinical trials of its complement C3 inhibitor, ... and multiple ascending dose studies designed to assess ... of subcutaneous injection in healthy adult volunteers. ... either as a single dose (ranging from 45 ...
Breaking Biology Technology: